<SEC-DOCUMENT>0001193125-25-315272.txt : 20251211
<SEC-HEADER>0001193125-25-315272.hdr.sgml : 20251211
<ACCEPTANCE-DATETIME>20251211100203
ACCESSION NUMBER:		0001193125-25-315272
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251211
DATE AS OF CHANGE:		20251211

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1227

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		251563783

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d84789ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549</B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROXY
STATEMENT PURSUANT TO SECTION 14(A) OF THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant&#8194;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other
than the Registrant&#8194;&#9744; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material under <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>STAAR SURGICAL COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules
<FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>On December&nbsp;11, 2025, STAAR Surgical Company (&#8220;STAAR&#8221; or the &#8220;Company&#8221;)
issued the following press release: </I></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g84789g1211111848882.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STAAR Surgical Sets the Record Straight Regarding its </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Robust <FONT STYLE="white-space:nowrap">Go-Shop</FONT> Process </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Activist Investors Have Twisted Facts Regarding STAAR&#8217;s Engagement with a Potentially Interested Party During <FONT
STYLE="white-space:nowrap">Go-Shop</FONT> Process </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The Potentially Interested Party Reached Out on Day 21 of <FONT
STYLE="white-space:nowrap">30-Day</FONT> <FONT STYLE="white-space:nowrap">Go-Shop</FONT> Process and Refused to Sign an NDA Even without a Standstill </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Broadwood Partners and Yunqi Capital Continue to Distort the Truth for Their Own Benefit </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LAKE FOREST, Calif. &#8212; December&nbsp;11, 2025 &#8212; STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of
Implantable Collamer<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Lenses (EVO ICL<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>) for vision correction, today&nbsp;issued the following statement to correct misinformation
regarding its robust <FONT STYLE="white-space:nowrap">go-shop</FONT> process to evaluate available alternatives to the pending merger with Alcon (SIX/NYSE: ALC). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broadwood Partners, L.P. (&#8220;Broadwood&#8221;) falsely alleges there was a credible buyer who had a strong interest in acquiring STAAR and that STAAR
management attempted to &#8220;run the clock&#8221; on a <FONT STYLE="white-space:nowrap">go-shop</FONT> period in order to &#8220;ward off this well-established private equity firm.&#8221; That is patently false. Broadwood is again twisting facts
related to STAAR&#8217;s engagement with parties during the <FONT STYLE="white-space:nowrap">go-shop</FONT> process, and this is just their latest attempt to derail STAAR&#8217;s efforts to maximize value for all stockholders. Yunqi Capital
(&#8220;Yunqi&#8221;) has also <FONT STYLE="white-space:nowrap">re-iterated</FONT> the Broadwood fallacy that there was another &#8220;credible buyer,&#8221; and suggested that STAAR should address these accusations. STAAR agrees with Yunqi that it
is important to set the record straight. The facts are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FountainVest, which STAAR believes is the party referenced by Broadwood and Yunqi as the &#8220;credible
buyer&#8221; in their recent public statements, waited until day 21 of the <FONT STYLE="white-space:nowrap">30-day</FONT> <FONT STYLE="white-space:nowrap">go-shop</FONT> period (on November&nbsp;27, 2025) before reaching out to STAAR. Notably,
FountainVest did not previously indicate any interest in acquiring STAAR prior to the signing of the Alcon merger agreement nor during the post-signing &#8220;window-shop&#8221; period. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nevertheless, STAAR&#8217;s CEO responded to FountainVest <B><I>the very next day</I></B>, day 22 of the <FONT
STYLE="white-space:nowrap">go-shop</FONT> process,<B><I> </I></B>and connected them with STAAR&#8217;s advisors at Citi. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On day 23 of the <FONT STYLE="white-space:nowrap">go-shop</FONT> process, Citi engaged in a discussion with
FountainVest and provided it with STAAR&#8217;s standard draft nondisclosure agreement (&#8220;NDA&#8221;). As is customary in a sell-side auction, the draft included a standstill provision. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The draft NDA that STAAR provided FountainVest was the same form provided to other interested parties during the <FONT
STYLE="white-space:nowrap">go-shop</FONT> process. Of the 21 third parties that were contacted during the <FONT STYLE="white-space:nowrap">go-shop,</FONT> only two requested and signed an NDA. In each case, changes to the form NDA were requested,
including modifications to the standstill provision, which STAAR agreed to, and each of those parties received confidential information and management presentations to facilitate their evaluation of STAAR. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Despite outreach by Citi, FountainVest did not return a draft of the NDA <B><I>for 5 days</I></B>, sending its
markup (which, among other things, deleted the standstill provision) shortly before midnight on day 28 of the <FONT STYLE="white-space:nowrap">go-shop</FONT> process. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Within 24 hours </I></B>thereafter, on day 29 of the <FONT STYLE="white-space:nowrap">go-shop</FONT>
process, STAAR responded to FountainVest with a revised NDA that accepted FountainVest&#8217;s deletion of the standstill. Despite this, FountainVest declined to execute the NDA. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <FONT STYLE="white-space:nowrap">30-day</FONT> <FONT STYLE="white-space:nowrap">go-shop</FONT> period expired
at 11:59 p.m. Eastern Time on December&nbsp;6, 2025, and no proposals were received by STAAR. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Within hours after STAAR announced the expiration of the <FONT STYLE="white-space:nowrap">go-shop,</FONT>
Broadwood issued a press release criticizing the results of the <FONT STYLE="white-space:nowrap">go-shop</FONT> process and disclosing detailed information regarding STAAR&#8217;s process and form of NDA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors should ask: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>If FountainVest was a &#8220;credible buyer,&#8221; why wait until so far into the <FONT
STYLE="white-space:nowrap">go-shop</FONT> process to contact STAAR and why were they so slow to respond to STAAR&#8217;s proposed NDA?</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>How did Broadwood know about the process and STAAR&#8217;s form of NDA? Is Broadwood working in concert with
FountainVest in an effort to derail the process? </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>What role did Broadwood play in manufacturing purported interest by Party A, B and C, who did not even request
an NDA nor show interest in conducting diligence for a potential acquisition?</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">STAAR and its advisors engaged with FountainVest in
good faith and encouraged them to execute an NDA, engage with management, and submit an acquisition proposal for the Board&#8217;s consideration.&nbsp;Broadwood&#8217;s allegation that STAAR &#8220;ran the clock&#8221; on the <FONT
STYLE="white-space:nowrap">go-shop</FONT> process is false and misleading. While the STAAR Board was focused on evaluating all opportunities to maximize value for stockholders, it appears that Broadwood was focused on undermining STAAR&#8217;s <FONT
STYLE="white-space:nowrap">go-shop</FONT> process. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephen Farrell, CEO of STAAR, said, &#8220;This is just another example of the misinformation campaign
being conducted by Broadwood. This is a pattern, just like Broadwood&#8217;s inaccurate characterization of STAAR&#8217;s growth rate and its disconnected perspective of market conditions in China.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;We continue to have confidence in our ability to grow the business in the long term, albeit at a significantly lower rate than we enjoyed from 2020 to
2023,&#8221; said Mr.&nbsp;Farrell. &#8220;However, we have struggled the last few years to grow our procedure volumes in China, and those challenges continue to be a hurdle for STAAR. The softness that we experienced in Q2 and Q3 has continued so
far in Q4.&nbsp;Now is the right time to sell, and Alcon has proven to be the right buyer.&#8221; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STAAR Stockholders Have a Choice
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stockholders have a choice - a certain and substantial premium or a multiyear journey starting at a much lower price, led by a
misinformed activist who lacks knowledge of this market and has a poor track record of activism. We encourage stockholders to accept Alcon&#8217;s increased <FONT STYLE="white-space:nowrap">all-cash</FONT> offer of $30.75 per share - a 74% premium
to the <FONT STYLE="white-space:nowrap">90-day</FONT> VWAP &#8211; representing certain and immediate value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>STAAR will hold a virtual Special Meeting
of Stockholders on December&nbsp;19, 2025 at 8:30 a.m. (Pacific Time). Stockholders of record as of the close of business on October&nbsp;24, 2025, are entitled to vote at the meeting. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Alcon merger agreement, as revised on December&nbsp;9, 2025, represents a 74% premium to STAAR&#8217;s <FONT STYLE="white-space:nowrap">90-day</FONT>
Volume Weighted Average Price and a 66% premium to the closing price of STAAR common stock on August&nbsp;4, 2025. We encourage shareholders to reach their own informed conclusions based on the facts and to ensure their voices are heard at the
special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders with questions about voting their shares should contact STAAR&#8217;s proxy solicitor, Innisfree M&amp;A Incorporated: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For stockholders: +1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">877-750-8233</FONT></FONT>
(toll-free from the U.S. and Canada) or +1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">412-232-3651</FONT></FONT> (from other countries) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For banks and brokerage firms: +1
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-750-5833</FONT></FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About STAAR Surgical </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need
for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL&#8217;s are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the
eye&#8217;s natural crystalline lens. Its EVO ICL<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3&nbsp;million ICLs in over 75
countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit www.EVOICL.com. To learn more about STAAR,
visit www.staar.com. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information About the Merger and Where to Find It </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication relates to the proposed transaction involving STAAR. In connection with the proposed transaction, STAAR has filed relevant materials with
the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), including STAAR&#8217;s definitive proxy statement on Schedule 14A (the &#8220;Proxy Statement&#8221;), on September&nbsp;16, 2025. The Proxy Statement was first sent to STAAR
stockholders on September&nbsp;16, 2025, and was thereafter supplemented. This communication is not a substitute for the Proxy Statement or any other document that STAAR may file with the SEC or send to its stockholders in connection with the
proposed transaction. BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF STAAR ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO, IN CONNECTION
WITH THE PROPOSED TRANSACTION WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the documents (when available) free of charge at the
SEC&#8217;s website, www.sec.gov, or by visiting STAAR&#8217;s investor relations website, https://investors.staar.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Offer or Solicitation
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication is for informational purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the
solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise,
nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants in the
Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under SEC rules, STAAR and certain of its directors, executive officers and other members of management and employees may be deemed to be
participants in the solicitation of proxies from the holders of STAAR&#8217;s common stock in connection with the proposed transaction. Information about the directors and executive officers of STAAR and their ownership of STAAR&#8217;s common stock
is set forth in the Proxy Statement, the definitive proxy statement for STAAR&#8217;s 2025 Annual Meeting of Stockholders (the &#8220;Annual Proxy Statement&#8221;), which was filed with the SEC on April&nbsp;24, 2025 (and which is available
at&nbsp;https://www.sec.gov/ix?doc=/Archives/edgar/data/0000718937/000095017025058174/staa-20250424.htm), including the sections captioned &#8220;Compensation of Directors,&#8221; &#8220;Information Regarding Executive Officers&#8221; and
&#8220;Security Ownership of Principal Shareholders and Management,&#8221; or its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;27, 2024, which was filed with the SEC on February&nbsp;21, 2025
(and which is available at&nbsp;https://www.sec.gov/ix?doc=/Archives/edgar/data/0000718937/000095017025024813/staa-20241227.htm), and in other documents filed by STAAR with the SEC. To the extent holdings of such participants in STAAR&#8217;s
securities have changed since the amounts described in the Proxy Statement, such changes have been reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC by STAAR&#8217;s
directors </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and executive officers. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitation and a
description of their direct and indirect interests, by security holdings or otherwise, will be contained in other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information covered by
this communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often contain words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;may,&#8221; and similar terms. All statements in this communication that are not
statements of historical fact are forward-looking statements. These forward-looking statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important factors that may cause actual results,
performance or achievements to be materially different from what is expressed or implied by the forward-looking statements, including, but not limited to: (1)&nbsp;the occurrence of any event, change or other circumstances that could give rise to
the termination of the Alcon merger agreement or could cause the consummation of the proposed transaction to be delayed or to fail to occur; (2)&nbsp;the failure to obtain approval of the proposed transaction from STAAR&#8217;s stockholders;
(3)&nbsp;the failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing conditions to the completion of the proposed transaction within the expected timeframes or at all; (4)&nbsp;risks related to
disruption of management&#8217;s attention from STAAR&#8217;s ongoing business operations due to the proposed transaction; (5)&nbsp;the effect of the announcement of the proposed transaction on the ability of STAAR to retain and hire key personnel
and maintain relationships with its customers, suppliers and others with whom it does business, or on its operating results and business generally; (6)&nbsp;the ability of STAAR to meet expectations regarding the timing and completion of the
transaction; (7)&nbsp;the outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction; (8)&nbsp;the possibility that STAAR&#8217;s stock price may decline significantly if the proposed transaction is not
consummated; and (9)&nbsp;other important factors set forth in the Proxy Statement under the caption &#8220;Risk Factors&#8221; and STAAR&#8217;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;27,
2024 under the caption &#8220;Risk Factors,&#8221; as any such factors may be updated from time to time in STAAR&#8217;s other filings with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements speak only as of the date they are made and, except as may be required under applicable law, STAAR undertakes no obligation to
update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>STAAR Contacts:&#8195; </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Niko Liu, CFA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States: +1
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">626-303-7902</FONT></FONT> (ext 3023) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hong Kong:
<FONT STYLE="white-space:nowrap">+852-6092-5076</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">nliu@staar.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">investorrelations@staar.com </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Connie Johnson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">626-303-7902</FONT></FONT> (ext 2207) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">cjohnson@staar.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lucas Pers / Alexandra Benedict </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joele Frank, Wilkinson Brimmer Katcher </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-895-8692</FONT></FONT> / +1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-895-8644</FONT></FONT> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g84789g1211111848882.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g84789g1211111848882.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] 2L# 2(  A$! Q$!_\0
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M?9-1MUG@WA]C?WAT-7J* ,"Q\&:#IM[%>6MB(YXCE'WL<<8]:WZ** "BBB@
MHI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@
M!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9
5H 6BDS1F@!:*3-&: %HI,T9H __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
